Influence of preoptic estradiol on behavioral and neural response to cocaine in female Sprague-Dawley rats.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Cocaine/*administration & dosage ; Estradiol/*administration & dosage ; Locomotion/*drug effects ; Preoptic Area/*drug effects; Animals ; Conditioning, Classical/drug effects ; Conditioning, Classical/physiology ; Dopamine Uptake Inhibitors/administration & dosage ; Estrogens/administration & dosage ; Female ; Locomotion/physiology ; Microinjections ; Ovariectomy/methods ; Preoptic Area/physiology ; Proto-Oncogene Proteins c-fos/biosynthesis ; Random Allocation ; Rats ; Rats, Sprague-Dawley

Rationale: Systemic estradiol (E2) increases the behavioral and neural response to cocaine. Where in the brain E2 acts to modulate cocaine response is not entirely clear. Evidence supports a role in this modulation for several candidate regions, including the medial preoptic area (mPOA).
Objectives: This study examined whether manipulation of E2 in the mPOA modulates differing behavioral responses to cocaine and whether this is reflected in differing levels of c-Fos in the NAc following cocaine administration.
Methods: Female rats received ovariectomies and bilateral cannulations of the mPOA. They then received either artificial cerebrospinal fluid (aCSF) or E2 microinjections into the mPOA the day before receiving systemic injections of saline or cocaine (5 or 10 mg/kg). Conditioned-place preference (CPP) to cocaine and locomotor activation were then obtained.
Results: Animals receiving 10 mg/kg, but not 5 mg/kg, cocaine developed significant CPP, and those receiving E2 into the mPOA expressed greater CPP than those receiving microinjections of only aCSF at both doses (p < 0.05, d > 0.80). Cocaine also caused significant psychomotor activation, but this was not dependent on microinjection of E2 in the mPOA. Finally, animals that received cocaine had increased NAc core and shell c-Fos relative to animals that received saline, with animals receiving both E2 microinjections and systemic cocaine expressing the highest activation in the caudal NAc, compared to rats receiving aCSF microinjections and systemic cocaine (p = 0.05, d = 0.70).
Conclusions: These results indicate that E2 in the mPOA facilitates the behavioral response and neural activation that follows cocaine administration. Furthermore, they confirm the close relationship between the mPOA and cocaine response.

J Neurosci. 2012 Sep 19;32(38):13309-26. (PMID: 22993446)
Eur J Neurosci. 2003 May;17 (10 ):2187-200. (PMID: 12786986)
Brain Struct Funct. 2015 Jul;220(4):2415-22. (PMID: 24878822)
J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):327-38. (PMID: 17936613)
Horm Behav. 2010 Jun;58(1):13-21. (PMID: 19733571)
Psychopharmacology (Berl). 1989;98(3):408-11. (PMID: 2501818)
J Neuroendocrinol. 2015 Apr;27(4):264-76. (PMID: 25599767)
J Neurosci. 2006 May 3;26(18):4901-7. (PMID: 16672664)
Neuropsychopharmacology. 2016 Jun;41(7):1897-906. (PMID: 26647972)
Trends Pharmacol Sci. 2004 May;25(5):273-9. (PMID: 15120494)
Behav Brain Res. 2012 Apr 21;230(1):11-20. (PMID: 22321458)
Eur J Pharmacol. 2012 Jul 5;686(1-3):50-4. (PMID: 22575525)
Eur J Pharmacol. 2008 Jun 10;587(1-3):147-54. (PMID: 18448094)
Neuropharmacology. 2013 Sep;72:236-49. (PMID: 23608737)
Horm Behav. 2004 Dec;46(5):509-19. (PMID: 15555492)
Front Neurosci. 2015 Mar 24;9:67. (PMID: 25852453)
Exp Clin Psychopharmacol. 2007 Oct;15(5):461-71. (PMID: 17924780)
J Neurosci. 1998 May 15;18(10):3967-76. (PMID: 9570823)
Brain Struct Funct. 2012 Apr;217(2):181-90. (PMID: 21987050)
Horm Behav. 2015 Jan;67:21-7. (PMID: 25456105)
Pharmacol Biochem Behav. 2010 Dec;97(2):284-92. (PMID: 20807549)
Pharmacol Biochem Behav. 2005 Sep;82(1):98-108. (PMID: 16111740)
J Neurosci. 2001 Mar 15;21(6):2085-93. (PMID: 11245692)
Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jan;23(1):99-132. (PMID: 10368859)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13632-7. (PMID: 18757761)
J Comp Neurol. 2003 Nov 17;466(3):409-21. (PMID: 14556297)
Pharmacol Biochem Behav. 2012 Oct;102(4):532-9. (PMID: 22750065)
Horm Behav. 2008 Nov;54(5):709-16. (PMID: 18721808)
Physiol Behav. 2007 Nov 23;92(4):617-28. (PMID: 17610916)
J Comp Neurol. 1986 May 15;247(3):364-82. (PMID: 3722443)
Behav Neurosci. 2013 Apr;127(2):293-302. (PMID: 23565937)
Physiol Behav. 2012 Jan 18;105(2):264-8. (PMID: 21893074)
Eur J Neurosci. 2015 Dec;42(12 ):3138-48. (PMID: 26536143)
Pharmacol Biochem Behav. 1991 Aug;39(4):923-7. (PMID: 1763112)
Neuropsychopharmacology. 2006 Jan;31(1):129-38. (PMID: 15920500)
Nat Neurosci. 2017 Mar;20(3):449-458. (PMID: 28135243)
Drug Alcohol Depend. 2014 Feb 1;135:22-8. (PMID: 24332790)

R01 DA032789 United States DA NIDA NIH HHS; T32 AA007471 United States AA NIAAA NIH HHS

Keywords: CPP; Cocaine; Estradiol; Medial preoptic area; Neuroendocrine; Nucleus accumbens

0 (Dopamine Uptake Inhibitors)
0 (Estrogens)
0 (Proto-Oncogene Proteins c-fos)
4TI98Z838E (Estradiol)
I5Y540LHVR (Cocaine)

Date Created: 20171206 Date Completed: 20190122 Latest Revision: 20190301

20221213

PMC5823731

10.1007/s00213-017-4800-9

29204804